HIGHLIGHTS
- who: Eva Versteijne from the Medical College of Wisconsin, United States University of Pittsburgh, United States have published the Article: Neoadjuvant Treatment for Resectable and Borderline Resectable Pancreatic Cancer: Chemotherapy or Chemoradiotherapy?, in the Journal: (JOURNAL)
- what: This study did not continue to phase III trial, because new, more effective chemotherapy regimens were developed . This trial was terminated prematurely because of slow accrual, and no results were presented .
- how: In this trial the neoadjuvant chemotherapy consisted of full-dose gemcitabine with the rationale that the chemotherapy dose in earlier studies was considered too . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.